Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 115.66M | 117.63M | 111.12M | 116.91M | 118.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 115.66M | 117.63M | 111.12M | 116.91M | 118.29M |
| Cost of Revenue | 20.48M | 20.44M | 19.29M | 27.09M | 32.80M |
| Gross Profit | 95.19M | 97.20M | 91.83M | 89.83M | 85.50M |
| SG&A Expenses | 95.55M | 89.70M | 93.49M | 93.34M | 101.58M |
| Depreciation & Amortization | 23.72M | 30.76M | 30.76M | 30.76M | 30.76M |
| Other Operating Expenses | -- | -- | -12.55M | -12.55M | -12.55M |
| Total Operating Expenses | 139.75M | 140.90M | 131.00M | 138.63M | 152.59M |
| Operating Income | -24.08M | -23.26M | -19.88M | -21.72M | -34.30M |
| Income Before Tax | -304.44M | -296.02M | -18.58M | -21.07M | -29.85M |
| Income Tax Expenses | -41.02M | -43.17M | -2.63M | -155.00K | 28.37M |
| Earnings from Continuing Operations | -263.43 | -252.85 | -15.95 | -20.92 | -58.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -263.43M | -252.85M | -15.95M | -20.92M | -58.22M |
| EBIT | -24.08M | -23.26M | -19.88M | -21.72M | -34.30M |
| EBITDA | 551.00K | 8.40M | 11.91M | 9.94M | -2.11M |
| EPS Basic | -212.10 | -203.59 | -12.52 | -16.54 | -63.02 |
| Normalized Basic EPS | -27.97 | -27.43 | -24.28 | -25.24 | -35.92 |
| EPS Diluted | -212.10 | -203.59 | -19.52 | -23.53 | -70.00 |
| Normalized Diluted EPS | -27.97 | -27.43 | -24.06 | -25.02 | -35.70 |
| Average Basic Shares Outstanding | 4.97M | 4.97M | 4.94M | 4.94M | 4.56M |
| Average Diluted Shares Outstanding | 4.97M | 4.97M | 5.91M | 5.91M | 5.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
